Nov 9 (Reuters) – Swiss drug developer Windward Bio Group AG is targeting a valuation of up to $1 billion in its US initial public offering, as a strong run for the biotech IPO market extends into
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Heekyong Yang, Kyu-seok Shim and Tom Westbrook SEOUL/SYDNEY, Nov 9 (Reuters) - Nvidia shares…
Nov 9 (Reuters) - Aberdeen have parted ways with manager Stephen Robinson after a disappointing…
Nov 9 (Reuters) - The European Union has sued IBM, French IT firm Atos and…
(The Nov 5 story was republished in error. The inconvenience caused is regretted.) By Sam…
Subscribers: Please update the following to the Reuters Daybook for today, Monday, November 9: ADDS…
* US CPI data due on Tuesday * Traders see 82.2% chance of Fed hike…